B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

128.06 -4.40 (-3.32%)
Streaming Delayed Price Updated: 10:37 AM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,106,012
Open 129.78
Bid (Size) 128.03 (2)
Ask (Size) 128.07 (2)
Prev. Close 132.46
Today's Range 127.24 - 130.13
52wk Range 78.19 - 148.15
Shares Outstanding N/A
Dividend Yield 1.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Hims & Hers stock has been surging since May, but has its valuation gotten too rich? 
Via The Motley Fool
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily

Performance

YTD
+25.41%
+25.41%
1 Month
-10.44%
-10.44%
3 Month
+3.26%
+3.26%
6 Month
+10.60%
+10.60%
1 Year
+61.75%
+61.75%

More News

Read More
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
Via The Motley Fool
Smart Money Is Betting Big In NVO Options
Via Benzinga
Novo Nordisk Unusual Options Activity For July 26
Via Benzinga
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Via InvestorPlace
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Via InvestorPlace
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
Via Benzinga
Exposures Product Safety
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Via Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Via The Motley Fool
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.